Brooke Esteves

1.4k total citations · 1 hit paper
31 papers, 662 citations indexed

About

Brooke Esteves is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Reproductive Medicine. According to data from OpenAlex, Brooke Esteves has authored 31 papers receiving a total of 662 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 14 papers in Reproductive Medicine. Recurrent topics in Brooke Esteves's work include Ovarian cancer diagnosis and treatment (14 papers), Renal cell carcinoma treatment (12 papers) and Cancer Genomics and Diagnostics (8 papers). Brooke Esteves is often cited by papers focused on Ovarian cancer diagnosis and treatment (14 papers), Renal cell carcinoma treatment (12 papers) and Cancer Genomics and Diagnostics (8 papers). Brooke Esteves collaborates with scholars based in United States, Spain and Italy. Brooke Esteves's co-authors include Jiuzhou Wang, Toon Van Gorp, Ursula A. Matulonis, Andrew Strahs, Pankaj Bhargava, Ana Oaknin, Michael Method, Jason Konner, Domenica Lorusso and Philipp Harter and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Brooke Esteves

31 papers receiving 652 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study

2023 220 citations Ursula A. Matulonis, Domenica Lorusso et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Brooke Esteves

Since Specialization

Citations

This map shows the geographic impact of Brooke Esteves's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brooke Esteves with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brooke Esteves more than expected).

Fields of papers citing papers by Brooke Esteves

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brooke Esteves. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brooke Esteves. The network helps show where Brooke Esteves may publish in the future.

Co-authorship network of co-authors of Brooke Esteves

This figure shows the co-authorship network connecting the top 25 collaborators of Brooke Esteves. A scholar is included among the top collaborators of Brooke Esteves based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brooke Esteves. Brooke Esteves is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Mirvetuximab soravtansine in folate receptor alpha (FRα)–high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial 2024 ·International Journal of Gynecological Cancer ·Robert L. Coleman, Domenica Lorusso, Ana Oaknin, Sabrina Chiara Cecere, Hannelore Denys, Nicoletta Colombo, Toon Van Gorp, Jason Konner, Margarita Romeo, Philipp Harter, Conleth G. Murphy, Yuemei Wang, Brooke Esteves, Michael Method, Ursula A. Matulonis	11
2	Reply to Z.R. McCaw et al 2023 ·Journal of Clinical Oncology ·Ursula A. Matulonis, Domenica Lorusso, Ana Oaknin, Sandro Pignata, Andrew Dean, Hannelore Denys, Nicoletta Colombo, Toon Van Gorp, Jason Konner, Margarita Romeo, Philipp Harter, Conleth G. Murphy, Jiuzhou Wang, (unknown), Brooke Esteves, Michael Method, Robert L. Coleman	2
3	Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study 2023 ·Obstetrical & Gynecological Survey ·Ursula A. Matulonis, Domenica Lorusso, Ana Oaknin, Sandro Pignata, Andrew Dean, Hannelore Denys, Nicoletta Colombo, Toon Van Gorp, Jason Konner, Margarita Romeo, Philipp Harter, Conleth G. Murphy, Jiuzhou Wang, (unknown), Brooke Esteves, Michael Method, Robert L. Coleman	4
4	Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study breakdown → 2023 ·Journal of Clinical Oncology ·Ursula A. Matulonis, Domenica Lorusso, Ana Oaknin, Sandro Pignata, Andrew Dean, Hannelore Denys, Nicoletta Colombo, Toon Van Gorp, Jason Konner, Margarita Romeo, Philipp Harter, Conleth G. Murphy, Jiuzhou Wang, (unknown), Brooke Esteves, Michael Method, Robert L. Coleman	220
5	Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor‐α positive ovarian cancer: The antibody–drug conjugate, payload and metabolite 2023 ·British Journal of Clinical Pharmacology ·Ya‐Ping Tu, (unknown), (unknown), H. Maxime Lagraauw, Callum M. Sloss, Michael Method, Brooke Esteves, Eric H. Westin, Anna Berkenblit	5
6	Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Evaluation of sequence of therapy on anti-tumor activity in the SORAYA study (002) 2023 ·Gynecologic Oncology ·Robert L. Coleman, Ana Oaknin, Sandro Pignata, Hannelore Denys, Nicoletta Colombo, Toon Van Gorp, Jason Konner, Margarita Romeo, Philipp Harter, Conleth G. Murphy, Brooke Esteves, Michael Method, Domenica Lorusso, Ursula A. Matulonis	1
7	O011/#496 Mirvetuximab soravtansine and bevacizumab in folate receptor αlpha-positive ovarian cancer: efficacy in patients with and without prior bevacizumab 2022 ·David M. O’Malley, Ana Oaknin, Ursula A. Matulonis, Gina Mantia-Smaldone, Peter Lim, Cesar M. Castro, Diane Provencher, Sanaz Memarzadeh, Michael Method, Jiuzhou Wang, Brooke Esteves, Kathleen N. Moore, Lucy Gilbert	2
8	Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: Final analysis. 2021 ·Journal of Clinical Oncology ·David M. O’Malley, Ana Oaknin, Ursula A. Matulonis, Gina Mantia-Smaldone, Peter Lim, Cesar M. Castro, Diane Provencher, Sanaz Memarzadeh, Patrick A. Zweidler‐McKay, Jiuzhou Wang, Brooke Esteves, Kathleen N. Moore, Lucy Gilbert	18
9	MIRASOL (GOG 3045/ENGOT OV-55): A randomized, open-label, phase III study of mirvetuximab soravtansine versus investigator’s choice of chemotherapy in advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate-alpha (FRα) expression. 2020 ·Journal of Clinical Oncology ·Kathleen N. Moore, Toon Van Gorp, Jiuzhou Wang, Brooke Esteves, Patrick A. Zweidler‐McKay	9
10	Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Final findings from the FORWARD II study. 2019 ·Journal of Clinical Oncology ·David M. O’Malley, Ursula A. Matulonis, Michael J. Birrer, Cesar M. Castro, Ignace Vergote, Lainie P. Martin, Gina Mantia-Smaldone, Lucy Gilbert, Antonio González-Martı́n, Raquel Bratos, Brooke Esteves, Karim Malek, Kathleen N. Moore	5
11	Single and multiple ascending-dose study of glucagon-receptor antagonist RN909 in type 2 diabetes: a phase 1, randomized, double-blind, placebo-controlled trial 2018 ·Endocrine ·Barry Gumbiner, Brooke Esteves, (unknown), Tenshang Joh, Pamela D. Garzone, Alison Forgie, Chandrasekhar Udata	13
12	A Phase Ib Study of the VEGF Receptor Tyrosine Kinase Inhibitor Tivozanib and Modified FOLFOX-6 in Patients With Advanced Gastrointestinal Malignancies 2014 ·Clinical Colorectal Cancer ·Corina N.A.M. Oldenhuis, Walter J. Loos, Brooke Esteves, Leni van Doorn, Monette Cotreau, Andrew Strahs, (unknown), Jourik A. Gietema, Elisabeth G.E. de Vries, Ferry A.L.M. Eskens	8
13	Tivozanib in patients treatment-naive for metastatic renal cell carcinoma: A subset analysis of the phase III TIVO-1 study. 2013 ·Journal of Clinical Oncology ·Cora N. Sternberg, Tim Eisen, Piotr Tomczak, Andrew Strahs, Brooke Esteves, Anna Berkenblit, Robert J. Motzer	8
14	Efficacy and safety data from patients with advanced renal cell cancer treated with tivozanib hydrochloride after progression on sorafenib. 2013 ·Journal of Clinical Oncology ·Robert J. Motzer, Dmitry Nosov, Piotr Tomczak, Anna Berkenblit, Brooke Esteves, Andrew Strahs, Thomas E. Hutson	4
15	Rates of dose adjustment in patients treated with tivozanib versus sorafenib in the phase III TIVO-1 study. 2013 ·Journal of Clinical Oncology ·Thomas E. Hutson, Dmitry Nosov, Mihai Hârza, Brooke Esteves, Andrew Strahs, Anna Berkenblit, Robert J. Motzer	3
16	Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma 2012 ·Journal of Clinical Oncology ·Dmitry Nosov, Brooke Esteves, Oleg Lipatov, (unknown), (unknown), Raju Titus Chacko, Dinesh Doval, Andrew Strahs, William J. Slichenmyer, Pankaj Bhargava	86
17	Final results of a phase Ib study of tivozanib and FOLFOX6 in patients (pts) with advanced gastrointestinal (GI) tumors. 2012 ·Journal of Clinical Oncology ·Ferry A.L.M. Eskens, Corina N.A.M. Oldenhuis, Walter J. Loos, Brooke Esteves, Leni van Doorn, Monette Cotreau, Pankaj Bhargava, Joshua Zhang, Andrew Strahs, (unknown), Jourik A. Gietema	3
18	Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors 2011 ·Clinical Cancer Research ·Ferry A.L.M. Eskens, Maja J.A. de Jonge, Pankaj Bhargava, Toshiyuki Isoe, Monette Cotreau, Brooke Esteves, Kunihiko Hayashi, Herman Burger, Maarten Thomeer, Leni van Doorn, Jaap Verweij	89
19	Abstract B60: Combination of tivozanib (AV-951) and temsirolimus in patients with renal cell carcinoma (RCC): Preliminary results from a phase 1 trial 2009 ·Molecular Cancer Therapeutics ·Mayer Fishman, Sandy Srinivas, Ralph J. Hauke, Robert J. Amato, Brooke Esteves, (unknown), Monette Cotreau, Mohammed Al-Adhami, Pankaj Bhargava, Fairooz F. Kabbinavar	2
20	Abstract LB-201: Updated results from a Phase I study of AV-951 (KRN951), a potent and selective VEGFR-1, -2 and -3 tyrosine kinase inhibitor, in patients with advanced solid tumors 2008 ·Cancer Research ·Ferry A.L.M. Eskens, Maja J.A. de Jonge, Brooke Esteves, Monette Cotreau, Pankaj Bhargava, John L. Ryan, Leni van Doorn, Toshiyuki Isoe, Kunihiko Hayashi, Lena Ekman, Herman Burger, Jaap Verweij	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact